3 Sep 2020

VIDEO: SGS vs COVID-19: Biologics Characterization Services

SGS' integrated network of laboratories provides a wide range of essential services to support the fight against COVID-19. We provide established expertise and resources for all aspects of biopharmaceuticals characterization, from physico-chemical properties, to primary, secondary, and tertiary structures, as well as aggregation.
For more information, contact [email protected] or visit:

Content provided by our supplier

SGS Group Management SA

  • CH
  • 2020
    On CPHI since
Company types

Other Content from SGS Group Management SA (2)

  • News SGS Joins Oxford University Consortium Led by the Jenner Institute to Develop COVID-19 Vaccine

    In a consortium led by the Jenner Institute, Oxford University, SGS has joined forces with specialists in infectious diseases, research and innovation, and pharmaceuticals to rapidly develop, scale-up and produce a potential vaccine called ChAdOx1 nCov-19
  • Brochure Analytical Testing and Quality Control Solutions

    Bringing a compound from the laboratory to the market is a long and winding road with a great number of scientific, safety and regulatory challenges. SGS has been offering high quality analytical testing and clinical research services to support drug research, registration and production. 
    SGS leverages its conveniently located network of laboratories and clinical trial facilities present in North America, Europe and Asia-Pacific, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. 
    Our experts provide effective and efficient testing solutions for analytical development, biologics characterization, biosafety and quality control, as well as clinical research services. We perform a variety of tests that are bespoke, client-specific and support the full clinical development, from Phase I First-in-Human trials in our Clinical Pharmacology Units to Phase II and Phase III studies in patients.